EATG » Projects » European HIV Vaccine Alliance – EHVA

European HIV Vaccine Alliance – EHVA

b11769e924

EHVA – EUROPEAN HIV VACCINE ALLIANCE, AN EU PLATFORM FOR THE DISCOVERY AND EVALUATION OF NOVEL PROPHYLACTIC AND THERAPEUTIC VACCINE CANDIDATES

Project aims: To develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The MVP includes four components: 1) Discovery, 2) Immune Profiling, 3) Data Management, Integration and Down-Selection, and 4) Clinical Trials.

Project leader: Institut national de la santé et de la recherche médicale (INSERM)

Main partners: Involves 39 institutions including Universities, Research Institutes, SMEs and larger industries.

EATG participation: Involved in WP 9: Therapeutic Vaccine Trials; WP 11: Dissemination and Exploitation. EATG is community partner in this project ensuring community feedback to the scientific developments within the project.

Duration: January 2016 – December 2020

Main funding source/programme: EC Horizon 2020

Budget: 50,000 EUR

Website: http://www.ehv-a.eu/

EATG contact person(s): Giorgio Barbareschi (office) at giorgio.barbareschi@eatg.org and Maria Dutarte (office) at maria.dutarte@eatg.org;  Giulio M Corbelli (EATG membership) at giuliomariacorbelli@gmail.com

1st Newsletter, July 2016

2nd Newsletter, December 2017

Announcement (November 2018):European HIV Vaccine Alliance (EHVA) initiates a clinical trial to test a novel therapeutic vaccine and immunotherapy drug